The Therapeutic Goods Administration has registered MSD's Zepatier (elbasvir/grazoprevir) with or without ribavirin, for the treatment of chronic hepatitis C virus genotype 1 and 4 infection in adults.
Zepatier is a once daily tablet taken for 12 weeks, with MSD offering patients the opportunity to receive treatment with the drug via a Product Familiarisation Program prior to a potential PBS listing.
MSD md Riad El-Dada said the company is continuing to work with the Pharmaceutical Benefits Advisory Committee in order to provide access to the drug with an anticipated PBS listing by 01 Dec.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Sep 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Sep 16
